Leveraged Finance Fights Melanoma

The Leveraged Finance Fights Melanoma benefit and cocktail party is planned for Wednesday, May 23, at the Summer Garden at Rockefeller Center in Midtown Manhattan. Tickets and sponsorship opportunities are available at the Melanoma Research Alliance website:www.curemelanoma.org/lffm.

Funds raised at the event will support the Melanoma Research Alliance (MRA), the world’s largest private funder of melanoma research, which was founded in 2007 by Debra and Leon Black, under the auspices of the Milken Institute.

Since this event was launched in 2012, the leveraged finance community has come together and generously supported more than $8.6 million of cutting-edge research to make transforming advances in the prevention, diagnosis and staging, and treatment of melanoma.

This year, LFFM welcomes two new co-chairs to the event committee: AJ Murphy (BAML) and Geoff Oltmans (Silver Lake). AJ and Geoff join returning event co-chairs Brendan Dillon (UBS); Lee Grinberg (Elliott Management); George Mueller (KKR); Jeff Rowbottom (PSP Investments); Cade Thompson (KKR); and Trevor Watt (Hellman & Friedman).

2017 Leveraged Finance Fights Melanoma at the Rockefeller Center’s Summer Garden

Attendees include the biggest names in leveraged finance, from all of the top banks, many investment houses, several law firms, select issuers, and some private equity sponsors.

Kirkland & Ellis is a presenting sponsor. Platinum sponsors include Apollo; Bloomberg; Fitch Ratings; IPREO Debtdomain; Midcap Financial; PSP Investments; Simpson Thacher & Bartlett; and UBS. Gold sponsors are Block Communications; Cahill Gordon & Reindel; Carlyle Group; Guggenheim; Hellman & Friedman; Latham & Watkins; Macquarie; Milbank Tweed Hadley & McCloy; Mizuho Americas; Oaktree Capital; Shearman & Sterling; Skadden, Arps, Slate, Meagher & Flom; T. Rowe Price, Wells Fargo, and Weil Gotshal. For a full listing of sponsors, please visitwww.curemelanoma.org/lffm.

Due to ongoing operational support from its founders, 100% of donations to MRA go directly to support research programs working toward a cure for melanoma, the deadliest type of skin cancer. Since MRA began its work, 11 new treatments have been approved by the FDA. Research performed in the melanoma field continues to have rippling impacts in the whole oncology space.

The data that MRA-funded scientists are generating is informing research in over 30 cancers, including colon, breast, brain, pancreatic, kidney, prostate, bladder, leukemia, lymphoma, and lung. Tickets are $300. For further information about the event and to purchase tickets, please visitwww.curemelanoma.org/lffm.

Those seeking information about the event and sponsorship opportunities can contact Rachel Gazzerro of MRA at (202) 336-8947 or RGazzerro@curemelanoma.org.

Melanoma Research Alliance
Founded in 2007 under the auspices of the Milken Institute, with the generous support of Debra and Leon Black, the Melanoma Research Alliance exists to accelerate treatment options and find a cure for melanoma. As the largest nonprofit funder of melanoma research, it has dedicated $100 million and leveraged more than $90 million in addition towards its mission. Through its support, MRA has championed revolutions in immunotherapy, targeted therapies, novel combinations and diagnostics. Due to the ongoing support of its founders, 100 percent of donations to MRA go directly to its melanoma research program. MRA’s ability to fund wide-ranging research in melanoma is amplified by unique collaborations and partnerships with individuals, private foundations, and corporations (www.CureMelanoma.org).

© 2018 Private Equity Professional | May 2, 2018

Print Friendly, PDF & Email